Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer | Zendy

José Baselga | Zendy; Patricia Gómez | Zendy; Richard Greil | Zendy; Sofía Braga | Zendy; Miguel Ángel Climent | Zendy; Andrew Wardley | Zendy; Bella Kaufman | Zendy; Salomon M. Stemmer | Zendy; António Pêgo | Zendy; Arlene Chan | Zendy; J. Goeminne | Zendy; Marie-Pascale Graas | Zendy; Megan Kennedy | Zendy; Eva María Ciruelos Gil | Zendy; Andreas Schneeweiß | Zendy; Angela Zubel | Zendy; Jutta Groos | Zendy; Helena Melezínková | Zendy; Ahmad Awada | Zendy

Open Access

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

Author(s) -

José Baselga,

Patricia Gómez,

Richard Greil,

Sofía Braga,

Miguel Ángel Climent,

Andrew Wardley,

Bella Kaufman,

Salomon M. Stemmer,

António Pêgo,

Arlene Chan,

J. Goeminne,

Marie-Pascale Graas,

Megan Kennedy,

Eva María Ciruelos Gil,

Andreas Schneeweiß,

Angela Zubel,

Jutta Groos,

Helena Melezínková,

Ahmad Awada

Publication year - 2013

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2012.46.2408

Subject(s) - cetuximab , medicine , cisplatin , oncology , triple negative breast cancer , neutropenia , hazard ratio , regimen , phases of clinical research , clinical endpoint , breast cancer , chemotherapy , cancer , randomized controlled trial , confidence interval , colorectal cancer

Epidermal growth factor receptor is overexpressed in metastatic triple-negative breast cancers (mTNBCs), an aggressive subtype of breast cancer. Our randomized phase II study investigated cisplatin with or without cetuximab in this setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research